文献速递免疫规划妇幼与学校卫生传染病防控与疫情报告

孕期接种mRNA新冠疫苗对6月龄以下婴儿新冠相关住院的保护效果——17个州,2021年7月至2022年1月

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-02-18

为评估孕期完成2剂mRNA新冠疫苗基础免疫对6月龄以下婴儿新冠住院的保护效果,Overcoming COVID-19网络于2021年7月1日至2022年1月17日在17个州20家儿科医院开展检测阴性病例对照研究。379例住院婴儿中176例新冠病例、203例对照,中位月龄2个月,21%有至少一种基础疾病,22%的病例和对照为早产(<37周)。孕期接种对6月龄以下婴儿新冠住院的保护效果为61%(95%CI=31%-78%)。

要点

  • 孕期完成2剂mRNA新冠疫苗基础免疫对6月龄以下婴儿新冠住院的保护效果为61%(95%CI=31%-78%)。
  • 379例住院婴儿中176例为新冠病例、203例为对照,中位月龄2个月。
  • 21%的住院婴儿有至少一种基础疾病,22%的病例和对照为早产(<37周)。

核心结论

  • 孕期完成2剂mRNA新冠疫苗基础免疫可能有助于预防6月龄以下婴儿新冠住院。

研究设计与样本

  • Overcoming COVID-19网络于2021年7月1日至2022年1月17日在17个州20家儿科医院开展检测阴性病例对照研究。
  • 纳入379例住院婴儿(176例新冠病例、203例对照),中位月龄2个月,21%有至少一种基础疾病,22%的病例和对照为早产(<37周)。

主要发现

  • 孕期接种对6月龄以下婴儿新冠住院的保护效果为61%(95%CI=31%-78%)。

关键数值与推荐

  • mRNA新冠疫苗孕期接种推荐适用于妊娠期、哺乳期、正在尝试怀孕或未来可能怀孕者,以保护其免患新冠。

临床怎么用

  • 孕期完成2剂mRNA新冠疫苗基础免疫可能有助于预防6月龄以下婴儿新冠住院。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to get pregnant now, or who might become pregnant in the future, to protect them from COVID-19.§ Infants are at risk for life-threatening complications from COVID-19, including acute respiratory failure (1). Evidence from other vaccine-preventable diseases suggests that maternal immunization can provide protection to infants, especially during the high-risk first 6 months of life, through passive transplacental antibody transfer (2). Recent studies of COVID-19 vaccination during pregnancy suggest the possibility of transplacental transfer of SARS-CoV-2-specific antibodies that might provide protection to infants (3-5); however, no epidemiologic evidence currently exists for the protective benefits of maternal immunization during pregnancy against COVID-19 in infants. The Overcoming COVID-19 network conducted a test-negative, case-control study at 20 pediatric hospitals in 17 states during July 1, 2021-January 17, 2022, to assess effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization in infants. Among 379 hospitalized infants aged <6 months (176 with COVID-19 [case-infants] and 203 without COVID-19 [control-infants]), the median age was 2 months, 21% had at least one underlying medical condition, and 22% of case- and control-infants were born premature (<37 weeks gestation). Effectiveness of maternal vaccination during pregnancy against COVID-19 hospitalization in infants aged <6 months was 61% (95% CI = 31%-78%). Completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy might help prevent COVID-19 hospitalization among infants aged <6 months.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35176002. doi:10.15585/mmwr.mm7107e3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。